Thrombocytopenia Management

Initial Diagnostic Approach

The American Society of Hematology recommends HIV and Hepatitis C testing in patients with thrombocytopenia, as these are common secondary causes of immune thrombocytopenia 1, 2
The American Society of Hematology suggests antiphospholipid antibody panel to evaluate for antiphospholipid syndrome in patients with thrombocytopenia 1, 2
Helicobacter pylori testing should be considered in patients with thrombocytopenia, with eradication therapy administered if positive 1
Medication review is essential to identify potential causes of thrombocytopenia, including heparin products and antiplatelet agents 3

The American College of Chest Physicians recommends bleeding risk assessment based on multiple factors, including history of prior bleeding episodes, concurrent coagulopathy, and need for invasive procedures 2
Patients with thrombocytopenia should be assessed for bleeding risk, taking into account factors such as platelet count, concurrent coagulopathy, and need for invasive procedures 2

For patients with platelet counts <30,000/μL and symptomatic bleeding, the American Society of Hematology recommends initiating corticosteroids immediately 1, 2
The American Society of Hematology suggests first-line treatment options, including corticosteroids, intravenous immunoglobulin, and IV anti-D immunoglobulin, for patients with thrombocytopenia and bleeding 1, 2
For patients with severe bleeding, the American College of Chest Physicians recommends combining corticosteroids with intravenous immunoglobulin and platelet transfusion 2

The American College of Chest Physicians recommends immediately discontinuing all heparin products and initiating non-heparin anticoagulant in patients with suspected HIT 3, 6
For patients with HIT, the American College of Chest Physicians suggests using argatroban, lepirudin, or danaparoid as non-heparin anticoagulants 3, 6

The American Society of Hematology recommends splenectomy for patients who have failed corticosteroid therapy 1
The American Society of Hematology suggests thrombopoietin receptor agonists, such as romiplostim and eltrombopag, for patients at risk of bleeding who relapse after splenectomy or have contraindication to splenectomy 1
Rituximab may be considered for patients with refractory ITP, achieving a 60% response rate with onset in 1-8 weeks 7, 1, 2

The American College of Chest Physicians recommends platelet transfusion thresholds for various procedures, including lumbar puncture, central venous catheter insertion, and major surgery 2

The American College of Chest Physicians recommends weekly platelet count monitoring during dose adjustment phase of any treatment, and monthly monitoring following establishment of stable treatment dose 2